INM - InMed Pharmaceuticals Inc. Stock Price and Quote

INM | InMed Pharmaceuticals Inc. | [NASD]

Index	-	P/E	-	EPS (ttm)	-17.79	Insider Own	0.15%	Shs Outstand	3.33M	Perf Week	-10.00%
Market Cap	4.27M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.32M	Perf Month	5.00%
Income	-15.50M	PEG	-	EPS next Q	-	Inst Own	12.30%	Short Float / Ratio	1.95% / 0.11	Perf Quarter	-5.26%
Sales	2.30M	P/S	1.86	EPS this Y	12.60%	Inst Trans	27.53%	Short Interest	0.06M	Perf Half Y	-55.79%
Book/sh	3.72	P/B	0.34	EPS next Y	-	ROA	-104.90%	Target Price	-	Perf Year	-93.70%
Cash/sh	2.83	P/C	0.44	EPS next 5Y	-	ROE	-132.30%	52W Range	0.92 - 20.00	Perf YTD	-37.62%
Dividend	-	P/FCF	-	EPS past 5Y	2.80%	ROI	-189.70%	52W High	-93.70%	Beta	1.05
Dividend %	-	Quick Ratio	4.60	Sales past 5Y	-	Gross Margin	3.50%	52W Low	36.76%	ATR	0.13
Employees	13	Current Ratio	5.20	Sales Q/Q	233.30%	Oper. Margin	-	RSI (14)	50.15	Volatility	8.13% 9.80%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	90.20%	Profit Margin	-	Rel Volume	0.11	Prev Close	1.27
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	614.57K	Price	1.26
Recom	3.00	SMA20	1.43%	SMA50	1.15%	SMA200	-61.92%	Volume	64,768	Change	-0.79%

May-24-23 06:51PM	InMed to Participate in Upcoming Virtual Investor Events (Newsfile)
May-18-23 05:00PM	InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET (Newsfile) +20.87%
May-15-23 12:33PM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Mar-28-23 07:30AM	InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa (Newsfile) -9.45%
Mar-13-23 07:30AM	InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions (Newsfile) +7.62%
08:35AM	Loading…
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on March 8 Register Now (GlobeNewswire)
Mar-06-23 06:00PM	InMed to Participate in Upcoming Investor Events (Newsfile) +9.82%
Feb-17-23 05:00PM	InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-09-23 09:41PM	InMed Submits Form 12b-25 (GlobeNewswire)
Jan-10-23 07:30AM	InMed Provides Business Update and Milestones for 2023 (GlobeNewswire) +36.09%
Dec-15-22 06:17PM	InMed Announces Results of 2022 Annual General Meeting (GlobeNewswire) -7.00%
Dec-12-22 06:47PM	InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor (GlobeNewswire)
Nov-23-22 12:18PM	Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update (Zacks)
05:00PM	Loading…
Nov-21-22 05:00PM	InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) -6.16%
Nov-18-22 08:00AM	InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) -28.12%
Nov-17-22 10:32AM	InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program (Zacks)
07:30AM	InMed Provides Update on Management Changes (GlobeNewswire)
Nov-16-22 12:13PM	InMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson's (MarketWatch) +36.33%
07:00AM	InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding (GlobeNewswire)
Nov-11-22 06:51PM	InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-22 07:30AM	Registration Now Open For Tribe Publics Webinar Event "Exploring the Neuroprotective Qualities of Rare Cannabinoids" Featuring InMeds Management Team On November 17, 2022 (GlobeNewswire) +8.30%
Oct-26-22 07:30AM	InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week (GlobeNewswire) +9.12%
Oct-24-22 10:13AM	10 Best Pharma Stocks To Buy Now (Insider Monkey) -17.41%
Sep-23-22 12:29PM	InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update (GlobeNewswire) -19.51%
Sep-19-22 06:00PM	InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022 (GlobeNewswire) -8.13%
Sep-13-22 05:12PM	InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) -35.73%
Sep-09-22 05:00PM	InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market (GlobeNewswire) +24.24%
Sep-08-22 02:08PM	InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business (GlobeNewswire)
05:00PM	Loading…
Aug-23-22 05:00PM	InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria (GlobeNewswire)
Aug-09-22 07:30AM	InMed Announces Changes to its Board of Directors (GlobeNewswire)
Jul-25-22 07:30AM	InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa (GlobeNewswire)
Jul-18-22 07:30AM	InMed Announces Appointment of Chief Operating Officer (GlobeNewswire)
Jul-12-22 11:33PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (GlobeNewswire)
Jun-14-22 07:30AM	InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions (GlobeNewswire)
Jun-09-22 07:30AM	InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector (GlobeNewswire)
Jun-06-22 06:49PM	InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jun-02-22 08:00AM	InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -6.04%
May-13-22 08:45AM	InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-05-22 07:30AM	InMed to Supply Rare Cannabinoids to Radicle Sciences Radicle Energy Study to Assess the Health Effects of THCV (GlobeNewswire) -8.36%
May-03-22 12:00PM	InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids (ACCESSWIRE)
Apr-28-22 07:30AM	InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert (GlobeNewswire) +8.15%
Apr-21-22 07:30AM	InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector (GlobeNewswire)
Apr-19-22 07:30AM	InMed to Participate in Upcoming Investor Conferences in April and May 2022 (GlobeNewswire)
Mar-17-22 07:30AM	InMed Announces Management Changes (GlobeNewswire) +5.80%
Mar-08-22 07:30AM	InMed to Present at the 34th Annual Roth Conference (GlobeNewswire) -7.05%
Feb-16-22 07:30AM	InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT (ACCESSWIRE)
Feb-15-22 07:30AM	InMed Pharmaceuticals Strengthens its Commercial Leadership Team with the Appointment of Vice President of Sales and Marketing for BayMedica (GlobeNewswire)
Feb-14-22 08:45PM	InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:34PM	InMed Pharmaceuticals Reports Second Quarter Fiscal 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-10-22 07:30AM	InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022 (GlobeNewswire)
Jan-19-22 07:30AM	InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector (GlobeNewswire) +6.61%
Jan-05-22 07:30AM	InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook (GlobeNewswire)
Dec-30-21 07:30AM	Registration Now Open For Tribe Publics Webinar Event "Addressing The Increasing Demand For Rare Cannabinoids" Featuring InMeds Management Team On January 6, 2022 (GlobeNewswire)
Dec-20-21 07:30AM	InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma (GlobeNewswire)
Dec-17-21 07:57PM	InMed Announces Results of 2021 Annual General Meeting (GlobeNewswire)
Nov-23-21 07:30AM	InMed Pharmaceuticals to Participate in Cowens 4th Annual Cannabis Conference (GlobeNewswire)
Nov-18-21 12:23PM	44 Stocks Moving In Thursday's Mid-Day Session (Benzinga) -8.72%
Nov-17-21 08:25AM	InMed Pharmaceuticals (INM): Progress Across the Business (ACCESSWIRE) +39.29%
Nov-10-21 09:05AM	InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-21 07:30AM	InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid (GlobeNewswire)
Oct-22-21 12:48PM	35 Stocks Moving In Friday's Mid-Day Session (Benzinga) -15.18%
07:32AM	26 Stocks Moving in Friday's Pre-Market Session (Benzinga)
Oct-18-21 07:02AM	21 Stocks Moving in Monday's Pre-Market Session (Benzinga) +9.29%
Oct-15-21 11:14AM	InMed Pharmaceuticals Inc. Announces Completion of BayMedica Acquisition (Benzinga) -9.68%
Oct-13-21 04:30PM	InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids (GlobeNewswire)
Sep-30-21 08:46AM	4 Penny Stocks Insiders Are Buying (Benzinga)
07:30AM	InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa (GlobeNewswire)
Sep-24-21 12:31PM	InMed Pharmaceuticals Inc. Releases FY 2021 Financial Report And Corporate Update (Benzinga)
07:30AM	InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Sep-20-21 07:50AM	InMed Pharmaceuticals (INM): Acquiring BayMedica (ACCESSWIRE)
Sep-17-21 01:14PM	InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021 (GlobeNewswire)
07:30AM	InMed Pharmaceuticals and BayMedica Participating in Tribe Publics Webinar "Accelerating The Commercialization of Rare Cannabinoids" (GlobeNewswire)
Sep-13-21 11:47AM	InMed Pharmaceuticals Inc. Enters Agreement For 'Transformative' Acquisition Of Leading Manufacturer Of Rare Cannabinoids (Benzinga)
09:59AM	InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids (Benzinga)
08:43AM	Cannabis Industry Investor Presentations Now Available for On-Demand Viewing (CNW Group)
07:32AM	Cannabis Industry Investor Presentations Now Available for On-Demand Viewing (PR Newswire)
07:30AM	InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids (GlobeNewswire)
Sep-09-21 07:18PM	InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-07-21 04:04PM	InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th (PR Newswire)
Sep-03-21 08:35AM	Cannabis Executives Present: Cannabis Investor Conference September 8th & 9th (CNW Group)
Sep-02-21 08:35AM	Cannabis Industry Investor Conference: Company Executives Present September 8th & 9th (PR Newswire)
Aug-25-21 01:27PM	InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production Of Rare Cannabinoids At Pharmaceutical Levels (Benzinga)
Aug-12-21 12:00PM	InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference (GlobeNewswire)
Jul-02-21 04:15PM	InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
Jun-29-21 07:00AM	InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids (GlobeNewswire) +9.46%
07:00AM	InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules (GlobeNewswire)
Jun-28-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (GlobeNewswire)
Jun-22-21 12:29PM	InMed Pharmaceuticals to Webcast Live at Life Sciences Investor Forum June 24th (GlobeNewswire)
Jun-21-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021 (GlobeNewswire)
Jun-17-21 07:30AM	InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn in Advance of Commercial Scale Production (GlobeNewswire)
Jun-15-21 06:41AM	Is InMed Pharmaceuticals Inc. (INM) A Good Stock To Buy Now? (Insider Monkey)
Jun-09-21 11:30AM	InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference (GlobeNewswire)
May-13-21 09:15AM	InMed Pharmaceuticals, Inc. to Host Earnings Call (ACCESSWIRE) -16.86%
07:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results (GlobeNewswire)
May-06-21 07:30AM	InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results (GlobeNewswire)
May-04-21 07:30AM	InMed to Present at Canaccord Genuitys 5th Annual Global Cannabis Conference on May 11th, 2021 (GlobeNewswire)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience